Brief: Camurus Divests Episil Oral Liquid Business To Solasia
08/07/2022 07:33
July 8 (Reuters) - Solasia Pharma KK 4597.T :
* SOLASIA ACQUIRES EPISIL ORAL LIQUID BUSINESS FROM CAMURUS
* DURING A TRANSITION PERIOD UP TO MAY 2024, CAMURUS WILL CONTINUE TO PROVIDE CERTAIN
ASSISTANCE
SERVICES AT SOLASIA'S REQUEST
* UNDER TERMS OF AGREEMENT, SOLASIA HAS OBTAINED ASSETS AND RELEVANT WORLDWIDE LICENSING
RIGHTS TO
CONTINUE DEVELOPING, MANUFACTURING AND COMMERCIALIZING EPISIL
Source text for Eikon: ID:nWkr4B5njX
Further company coverage: 4597.T
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))